Home

Provides new pathways for biomarkers and drug discovery for cancer patients.  Background:
The gene Abelson interactor protein-1 (ABI1) encodes a member of the Abelson-interactor family of adaptor proteins. These proteins facilitate signal transduction as components of several multiprotein complexes, and regulate actin polymerization and cytoskeletal remodeling through interactions with Abelson tyrosine kinases. The androgen receptor (AR) protein functions as a steroid-hormone activated transcription factor. ABI1 and AR are widely expressed in human tissues. Many cancers show sex-specific tumorigenesis, tumor progression, and sensitivity to hormonal drugs. The ABI1-AR axis might play critical roles in these tissue and drug sensitivities and toxicities. For example, ABI1 regulates a specific subset of genes associated with prostate tumor progression. These genes are biomarkers and potential targets of tumor progression.
Technology Overview:  
This technology defines ABI1-AR reciprocal regulation involving two non-exclusive molecular mechanisms of ABI1-AR and ABI1-DNA interactions. ABI1-DNA binding activity predicts survival of prostate cancer patients. ABI1 binds AR via a multivalent interaction. The ABI1-AR transcriptional program is altered during tumor progression and by anti-androgen treatments, suggesting that ABI1 is a key plasticity regulator in PCa by coupling its actin regulatory and signaling functions to transcriptional regulation. ABI1-AR reciprocal regulation has far reaching implications for tumor plasticity and androgen-sensitive pathogenesis. These interactions are co-regulated during PCa evolution and clinical treatment promoting tumor plasticity and progression. This provides new paths for biomarker and drug design discovery in PCa. https://suny.technologypublisher.com/files/sites/adobestock_282277912.jpegAdvantages:  
•    Provides a novel mechanism for predicting survival rates among cancer patients.
•    May enable drug discovery for a wide variety of cancers. Applications:  
The primary applications for this technology are the development of biomarkers for assessing cancer patient survival rates, and drug discovery.  Intellectual Property Summary: US Provisional Patent Application Ser. No. 63/463,457, filed May 2, 2023. Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of biomarkers and/or therapeutics for cancer, including:
•    Pharmaceutical companies.
•    Hospitals.
•    Medical research laboratories.
•    Universities.

 

Enables high-quality emission computers tomography (ECT) whild reducing the patient's radiation exposure. BackgroundEmission computed tomography (ECT) is an important scientific and medical imaging technique. Clinical applications of ECT include detecting, staging and monitoring response to cancer therapy; detection and risk stratification of cardiovascular diseases; mapping regional blood flow in the brain; bone scans; pulmonary ventilation/perfusion scans; renal scans and many other applications. There is a great need to reduce radiation dose to the patients undergoing ECT examinations. However, dose reduction implies using less ionizing radiation, i.e. fewer gamma photons, which in turn leads to increased noise in the data and in the images reconstructed with conventional methods. Clearly, good quality ECT reconstructions from low-dose ECT examinations, ergo high-noise data, are in high demand. This demand may be met by applying novel advanced ECT reconstruction methods that subdue the noise while preserving diagnostic image quality.Technology Overview:  
This technology uses a computer to reconstruct transaxial images of the patient from projection data. The reconstruction process estimates mean radiotracer activity distribution inside the body of a patient. It is governed by molecular and/or functional processes and allows clinicians to arrive at diagnoses. The algorithm reconstructs the expected activity distribution, while suppressing noise and preserving the spatial resolution in the estimation. This method demonstrates superior performance vs. standard-of-care when the observed data are very noisy or incomplete. It allows clinicians to perform the clinically acceptable ECT examinations with a radiation dose that is two to six times lower than presently used for the standard-of-care ECT imaging. https://suny.technologypublisher.com/files/sites/adobestock_226212015.jpegAdvantages •    Allows lower radiation dose for patients undergoing ECT examinations without compromising the obtained images quality.
•    Provides good quality tomographic image reconstructions under high noise conditions. Applications:  Emission computed tomography (ECT). This is widely used for many medical applications, including:
•    Detecting, staging and monitoring response to cancer therapy.
•    Detection and risk stratification of cardiovascular diseases.
•    Mapping of regional blood flow in the brain.
•    Bone scans.
•    Pulmonary ventilation/perfusion scans.
•    Renal scans
… and many others.  Intellectual Property Summary: This technology is protected by U.S. Patent 9,460,494, “Methods and systems for inverse problem reconstruction and application to ECT reconstruction” 
Stage of Development: TRL 4 – Technology validated in lab Licensing Status: This technology is available for licensing. Licensing Potential: This technology would be of interest to any organization involved in ECT, including:
•    Medical imaging equipment manufacturers
•    Hospitals and medical laboratories
•    Educational and research laboratories
 ­

A serotonin release assay that requires no special training or expensive equipment, and produces results within hours.  Background:
Platelet serotonin release assay (SRA) is a widely-used clinical assay for diagnosing heparin-induced thrombocytopenia (HIT), a life-threatening complication of heparin treatment. The current SRA procedure entails sending patient serum to a facility for testing by radioactive serotonin uptake/release or by mass spectrometry. Both assay methods require specialized equipment and trained personnel, with a turnaround time typically between three to seven days. Unfortunately, the mortality of HIT increases significantly with each passing day. As a result, quicker SRA turnaround time could save lives. Ideally, point-of-care facilities would obtain SRA results within hours, using inexpensive equipment and no special training to perform.Technology Overview:  
This technology is a luminescent biosensor that changes from green to blue in the presence of a target analyte. The biosensor consists of two molecules. The first is a specially designed green-to-blue color-changing luminescent protein (nLuc-AFF). The second is one or more short (20-50 nucleotide) DNA hairpins or DNA aptamers of novel design. These bind the target DNA sequence, RNA sequence, small molecule, or protein. Upon binding, the AP-1 sequence becomes exposed and activates the biosensor. The biosensor can be readily adapted to recognize different targets by modifying the DNA component, using existing online DNA design tools. The color change is visible and detection/quantification is via cell phone camera. https://suny.technologypublisher.com/files/sites/adobestock_446068375.jpegAdvantages:  
•    Produces results within hours.
•    Requires no special training or expensive equipment.
•    Can be easily adapted to recognize a variety of targets.
 Applications:  
•    Improved platelet SRA for diagnosing HIT.
•    Rapid detection of virus or other pathogen infection, such as coronavirus or cytomegalovirus.
•    Rapid detection of disease biomarkers such as microRNA, metabolites, or aberrant proteins.
 Intellectual Property Summary:
Know-how basedStage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of methods for detection of HIT and other conditions. These include:
•    Pharmaceutics companies.
•    Hospitals.
•    Medical research laboratories.
•    Universities.

An easy-to-use method for rapidly, accurately, and non-invasively assessing flavivirus immunity by measuring various antibody classes present in saliva.  Background:
Flaviviruses (including dengue virus) are the most common vector-borne human viral pathogens in the world. Nearly 40% of the world’s population are at risk of infection with dengue virus alone, with nearly 400 million dengue virus infections occurring each year resulting in an estimated 20,000 deaths. There is currently an unmet need for a non-invasive, sensitive, and accurate point-of care assay capable of quantifying flavivirus-specific antibody immunity. In addition, the only currently available dengue virus vaccine is only recommended for use in individuals with preexisting dengue virus antibodies. Therefore, a rapid and non-invasive antibody test for assessing flavivirus immunity would allow for safer and more accurate vaccine administration in settings where venipuncture is not convenient.Technology Overview:  
This technology is a saliva-based assay to rapidly, accurately, and non-invasively assess flavivirus immunity by measuring various antibody classes present in saliva. Saliva is collected via an absorbent swab and separate proprietary protein-stabilization solution. The collection method is uncomplicated and can be self-performed. Once collected and placed in the stabilizer solution, the saliva is stable at room temperature for several days, for weeks at 4oC, or indefinitely below -20oC. Testing the saliva sample uses a diagnostics instrument and a custom-designed flavivirus antigen panel. The assay can differentiate the specificity of homotypic humoral immune responses to the dengue viruses (1-4), zika virus, and JE virus, as well as differentiate individuals with polytypic dengue virus immunity and those who previously experienced both dengue virus and zika virus infections. https://suny.technologypublisher.com/files/sites/110-2173adobestock_890015932.jpeg Advantages:  
•    Easy to use, can be self-administered without advanced training.
•    Non-invasive.
•    Rapid.
•    Accurate.
•    Can differentiate a variety of factors.  Applications:  
The primary application for this technology is the treatment of flaviviruses such as dengue virus. Intellectual Property Summary:
Know-How Based.Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of therapeutics for flaviviruses, including:
•    Pharmaceutics companies.
•    Hospitals.
•    Medical research laboratories.
•    Universities.
•    Humanitarian organizations.